Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Thomas McFall, Michael Trogdon, Anita C. Guizar, John F. Langenheim, Laura Sisk-Hackworth, Edward C. Stites
Abstract
The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why this combination of inhibitors is effective.
Topics & Concepts
KRASGTP'MutantWild typeChemistryCancer researchMutationBiologyBiochemistryGeneEnzymeProtein Kinase Regulation and GTPase SignalingCytokine Signaling Pathways and InteractionsATP Synthase and ATPases Research